Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for post-stroke depression
MOH_2022-07-20_011925Phase 2Not yet recruiting
- Sponsor
- דר' עינור בן אסאייג.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and post-stroke anxiety (PSA) comparing Maraviroc add-on with Placebo add-on (2 arms). Planned start Jul 2022; status: not yet recruiting.
02
Drugs
maraviroc
03
Conditions
major depressive disorder (MDD)post-stroke anxiety (PSA)
Beyond the preview
Go deeper on MOH_2022-07-20_011925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-20_011925.